scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH

scPharmaceuticals Stock Analysis & Ratings

scPharmaceuticals Stock Analysis Overview

Smart Score
6
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The scPharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

SCPH

SCPH Stock Stats

Previous Close$4.25
Open$4.31
Bid4 x 300
Ask4.15 x 100
Today’s Range$4.07 - $4.46
52-Week Range$3.48 - $8.20
Volume68.66K
Average Volume49.15K
Market Cap$114.89M
Beta0.36
P/E Ratio-4.0
EPS-1.04
Earnings DateMar 23, 2022

Company Description

scPharmaceuticals Inc

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Sector
Healthcare
Industry
Biotechnology
CEO
John H. Tucker
Employees
27
Website
www.scpharmaceuticals.com
ISIN
US8106481059
Address
2400 District Avenue, Burlington, MA, 01830, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

SCPH FAQ

What was scPharmaceuticals’s price range in the past 12 months?
scPharmaceuticals lowest stock price was $3.48 and its highest was $8.20 in the past 12 months.
    What is scPharmaceuticals’s market cap?
    scPharmaceuticals’s market cap is $114.89M.
      What is scPharmaceuticals’s price target?
      The average price target for scPharmaceuticals is $10.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $15.00 ,the lowest forecast is $6.00. The average price target represents 150.00% Increase from the current price of $4.2.
        What do analysts say about scPharmaceuticals?
        scPharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is scPharmaceuticals’s upcoming earnings report date?
          scPharmaceuticals’s upcoming earnings report date is Mar 23, 2022 which is in 61 days.
            How were scPharmaceuticals’s earnings last quarter?
            scPharmaceuticals released its earnings results on Nov 09, 2021. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.313 by $0.073.
              Is scPharmaceuticals overvalued?
              According to Wall Street analysts scPharmaceuticals’s price is currently Undervalued.
                Does scPharmaceuticals pay dividends?
                scPharmaceuticals does not currently pay dividends.
                What is scPharmaceuticals’s EPS estimate?
                scPharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does scPharmaceuticals have?
                scPharmaceuticals has 27,360,000 shares outstanding.
                  What happened to scPharmaceuticals’s price movement after its last earnings report?
                  scPharmaceuticals reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.313. Following the earnings report the stock price went down -10.095%.
                    Which hedge fund is a major shareholder of scPharmaceuticals?
                    Among the largest hedge funds holding scPharmaceuticals’s share is RA Capital Management. It holds scPharmaceuticals’s shares valued at 18M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis